REEPMEYER, GERRIT; GASSMANN, OLIVER; RÜTHER, FRAUKE - In: International Journal of Innovation Management (ijim) 15 (2011) 04, pp. 755-795
Few large pharmaceutical companies have recently discovered out-licensing of terminated R&D results as a way to recoup … of out-licensing. While out-licensing is usually done because of downstream concerns, our analysis shows that the company … partner firms based on their development capabilities, these out-licensing deals are characterized by an asymmetric …